The University of Chicago Header Logo

Connection

Scott E. Eggener to Prognosis

Back to Details
This is a "connection" page, showing publications Scott E. Eggener has written about Prognosis.
Scott E. Eggener
Connection Strength
1.653
Prognosis
  1. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
    View in: PubMed
    Score: 0.104
  2. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494.
    View in: PubMed
    Score: 0.099
  3. Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. BJU Int. 2019 11; 124(5):792-800.
    View in: PubMed
    Score: 0.096
  4. A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. Urology. 2019 04; 126:76-82.
    View in: PubMed
    Score: 0.093
  5. Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology. 2019 01; 123:186-190.
    View in: PubMed
    Score: 0.091
  6. Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma. J Urol. 2017 11; 198(5):1027-1032.
    View in: PubMed
    Score: 0.083
  7. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016 May; 34(5):687-93.
    View in: PubMed
    Score: 0.074
  8. Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 2015 Oct; 86(4):777-82.
    View in: PubMed
    Score: 0.073
  9. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98.
    View in: PubMed
    Score: 0.073
  10. Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol. 2015 Sep; 194(3):626-34.
    View in: PubMed
    Score: 0.072
  11. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct; 66(4):611-2.
    View in: PubMed
    Score: 0.067
  12. Global trends in testicular cancer incidence and mortality. Eur Urol. 2011 Aug; 60(2):374-9.
    View in: PubMed
    Score: 0.055
  13. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011 Mar; 185(3):869-75.
    View in: PubMed
    Score: 0.054
  14. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132. J Urol. 2009 Jul; 182(1):396-7.
    View in: PubMed
    Score: 0.048
  15. The clinical diversity of postchemotherapy germ cell teratoma. Cancer. 2009 Mar 15; 115(6):1138-41.
    View in: PubMed
    Score: 0.047
  16. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May; 55(5):1073-4.
    View in: PubMed
    Score: 0.047
  17. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008 Sep; 180(3):873-8; discussion 878.
    View in: PubMed
    Score: 0.045
  18. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007 Feb 01; 109(3):528-35.
    View in: PubMed
    Score: 0.041
  19. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006 Jul 01; 24(19):3101-6.
    View in: PubMed
    Score: 0.039
  20. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol. 2005 Apr; 173(4):1150-5.
    View in: PubMed
    Score: 0.036
  21. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer. 2023 03; 182:144-154.
    View in: PubMed
    Score: 0.031
  22. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):460-474.
    View in: PubMed
    Score: 0.026
  23. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):475-483.
    View in: PubMed
    Score: 0.026
  24. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178.
    View in: PubMed
    Score: 0.024
  25. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424.
    View in: PubMed
    Score: 0.022
  26. Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. 2017 10; 3(4-5):487-497.
    View in: PubMed
    Score: 0.021
  27. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. Am J Surg Pathol. 2016 10; 40(10):1400-6.
    View in: PubMed
    Score: 0.020
  28. Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study. BJU Int. 2016 06; 117(6):914-22.
    View in: PubMed
    Score: 0.019
  29. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol. 2015 Dec; 68(6):1033-44.
    View in: PubMed
    Score: 0.018
  30. The volume of nonneoplastic parenchyma in a minimally invasive partial nephrectomy specimen: predictive factors and impact on renal function. J Endourol. 2014 Feb; 28(2):196-200.
    View in: PubMed
    Score: 0.016
  31. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct; 64(4):544-52.
    View in: PubMed
    Score: 0.016
  32. Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol. 2013 Jun; 189(6):2047-53.
    View in: PubMed
    Score: 0.015
  33. Short (= 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int. 2013 Apr; 111(4):559-63.
    View in: PubMed
    Score: 0.015
  34. Clinical and histologic predictors of renal function decline after laparoscopic partial nephrectomy. J Endourol. 2011 Sep; 25(9):1435-41.
    View in: PubMed
    Score: 0.014
  35. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5.
    View in: PubMed
    Score: 0.013
  36. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008 Dec 01; 26(34):5524-9.
    View in: PubMed
    Score: 0.011
  37. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.